Divis Laboratories Ltd, a leading manufacturer and exporter of APIs, intermediates, and nutraceutical ingredients, reported strong financial results for Q2FY26.
Financial Highlights:
- Revenues increased 16.12% year on year to ₹2,715 crore from ₹2,338 crore.
- Total expenses went up 13.12% to ₹1,948 crore from ₹1,722 crore.
- Consolidated net profit surged 35.1% to ₹689 crore from ₹510 crore.
- Earnings per share grew 35.09% to ₹25.95 from ₹19.21.
The company’s significant profit growth was driven by strong demand across global markets, operational efficiencies, and cost control initiatives. Divis also benefited from margin expansion amid competitive pressures in the pharmaceutical ingredients market.
Outlook:
Divis Laboratories is well positioned for continued growth with a robust order book, capacity expansions, and focused R&D investments. The Q2FY26 results reinforce the company’s leadership in the pharmaceutical ingredients space and its strategy for sustainable long-term value creation.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.